Andrographolide: A Comprehensive Scientific Overview

Introduction and Chemical Foundation

Andrographolide represents one of nature's most extensively studied bioactive compounds (1), a labdane diterpenoid lactone with the molecular formula C₂₀H₃₀O₅ and molecular weight of 350.44 g/mol (2). This white, crystalline compound exhibits an intensely bitter taste and possesses a complex three-dimensional molecular architecture featuring an electrophilic α-alkylidene-β-hydroxy-γ-butyrolactone moiety that enables covalent protein binding (3). The compound's unique bicyclic diterpene structure contains multiple chiral centers, high oxygen content, and no aromatic rings (4), contributing to its diverse biological activities.

Classified as an ent-labdane diterpenoid, andrographolide demonstrates poor water solubility but moderate lipophilicity, placing it in Biopharmaceutical Classification System Class III (5). The compound's chemical stability presents challenges, as its lactone ring structure makes it prone to hydrolysis, ring opening, and isomerization, particularly under aqueous conditions or elevated temperatures (6).

Natural Origins and Botanical Source

Andrographolide derives primarily from Andrographis paniculata (Burm. F.) Wall. ex Nees, commonly known as the "King of Bitters," Green Chiretta, or Kalmegh in traditional systems (7). This annual herbaceous plant belongs to the Acanthaceae family and grows 30-70 cm in height with characteristic lanceolate leaves and white flowers marked with purple streaks (8).

Native to peninsular India and Sri Lanka, A. paniculata has naturalized throughout tropical Asia, including Java, Malaysia, Indonesia, Philippines, Thailand, and parts of tropical America (9). The plant thrives from sea level to 500m elevation in various soil types, demonstrating remarkable adaptability to different growing conditions. Commercial cultivation has become essential due to exhaustion of wild resources (10), with major production centers in India, China, Thailand, and Indonesia.

The andrographolide content varies significantly across plant parts and geographic regions (11), ranging from 0.4-23 mg/g in plant materials depending on cultivation conditions, harvesting time, and processing methods. Leaves typically contain the highest concentrations, with optimal harvesting occurring during flowering stage (12).

Extraction and Production Methods

Traditional extraction methods rely primarily on alcohol-based solvents (13), with Soxhlet extraction using methanol achieving yields exceeding 60 μg/g. Modern commercial production employs sophisticated techniques including optimized solvent extraction with 70% ethanol at 70°C, achieving yields of 41.96 mg/g andrographolide (14).

Advanced extraction technologies have revolutionized production efficiency (15). Microwave-assisted extraction (MAE) using 60% aqueous methanol with 80W microwave power reduces extraction time to just 6 minutes while maintaining high yields (16). Three-phase partitioning (TPP) represents another innovative approach, achieving 26.55 mg/g yields with 62.5% efficiency under optimal conditions of 40% ammonium sulfate, pH 7, and 40°C temperature (17).

Recent breakthroughs in biosynthetic pathway elucidation have identified four key cytochrome P450 enzymes (ApCYP71D587, ApCYP71BE50, ApCYP706U5, and ApCYP72F1) that constitute the minimal andrographolide biosynthetic gene set (18). Metabolic engineering approaches using these enzymes in cell culture systems show promise for sustainable production, with adventitious root cultures producing 3.5-5.5 fold higher andrographolide content than natural plants (19).

Commercial Products and Market Analysis

Commercial products include capsules, tablets, liquid extracts, and powdered extracts with purity grades ranging from 5-99% andrographolide content. Products typically contain standardized extracts with 2-50% andrographolide, commonly providing 90-600mg daily dosages (20). Applications extend beyond dietary supplements to include functional foods, cosmetic formulations for anti-aging applications, and pharmaceutical preparations including injectable andrographolide sulfonate (21).

Therapeutic Benefits and Clinical Evidence

Andrographolide demonstrates remarkable therapeutic versatility supported by extensive clinical research (22). A comprehensive analysis of randomized controlled trials reveals significant efficacy for respiratory tract infections, with multiple systematic reviews confirming anti-inflammatory properties comparable to NSAIDs (23).

Anti-inflammatory effects represent the compound's most validated benefit, with IC50 values of 12.2 μM for IL-6 inhibition (24). Clinical applications include successful treatment of upper respiratory infections, bronchitis, and pneumonia, with multicenter randomized controlled trials demonstrating efficacy against mild-to-moderate COVID-19 pneumonia (25).

Hepatoprotective properties provide complete normalization of liver enzymes at doses of 200-800 mg/kg in animal models, achieved through antioxidant activity, restoration of endogenous antioxidant enzymes, and protection against various hepatotoxins (26). Anticancer research demonstrates activity against lung, gastric, and breast cancers through multiple mechanistic pathways (27).

Broad-spectrum antiviral activity includes effects against HIV, dengue, influenza, and SARS-CoV-2 through inhibition of viral replication and entry mechanisms (28). Autoimmune applications show promise, with a randomized, double-blind, placebo-controlled trial using 140 mg twice daily for 24 months demonstrating potential reduction in brain atrophy and disability progression in progressive multiple sclerosis patients (29).

Mechanisms of Action

Andrographolide operates through multiple molecular targets and signaling pathways (30), with NF-κB pathway inhibition representing the predominant mechanism. Network pharmacology analysis reveals the compound acts on hub targets including SRC, AKT1, TP53, STAT3, PIK3CA, MAPK1, MAPK3, VEGFA, JUN, and HSP90AA1, influencing PI3K/Akt, MAPK, JAK/STAT, HIF-1, and Nrf2 signaling pathways (31).

Cellular mechanisms encompass apoptosis induction through increased caspase-3 and caspase-9 activity (32), upregulation of pro-apoptotic proteins (Bax, Apaf-1), and downregulation of anti-apoptotic proteins (Bcl-2, Bcl-xL). The compound targets BAX protein to enhance mitochondrial-driven apoptosis while inhibiting pyruvate dehydrogenase kinase 1 (PDK1) to suppress aerobic glycolysis in cancer cells (33).

Antioxidant activity occurs through Nrf2 signaling pathway activation (34), increasing nuclear Nrf2 content and DNA binding to upregulate antioxidant enzyme expression. This multi-target approach provides therapeutic versatility across inflammatory, metabolic, and neoplastic conditions (35).

Safety Profile and Side Effects

Andrographolide demonstrates generally favorable safety when used appropriately (36), though specific risks require consideration. A systematic review and meta-analysis of clinical studies comparing andrographolide derivative medications to herbal preparations revealed that common mild to moderate side effects include gastrointestinal issues (diarrhea, nausea, abdominal pain, bitter taste), neurological symptoms (headache, fatigue), and dermatological reactions (rash, pruritus, urticaria) (37).

Serious adverse reactions primarily associate with injectable derivatives (38), including 97 cases of anaphylaxis with andrographolide derivative injections, 55 life-threatening anaphylactic reactions, and 5 deaths. Injectable forms demonstrate significantly higher adverse effect rates than herbal preparations, which show generally mild to moderate severity.

Dose-dependent toxicity becomes apparent at higher concentrations (39), with the No Observable Adverse Effect Level (NOAEL) established at 500 mg/kg/day in subacute studies. Absolute contraindications include pregnancy (potential miscarriage risk), breastfeeding (insufficient safety data), known allergies, and autoimmune diseases (potential symptom worsening) (40).

Drug interactions involve CYP450 enzyme inhibition (CYP1A2, CYP2C9, CYP3A4), potentially increasing side effects of aminophylline and other substrates (41). Documented interactions include effects on anticoagulants/antiplatelets (increased bleeding risk), antihypertensives (enhanced hypotensive effects), and immunosuppressants (therapeutic interference).

Animal Safety Studies

Toxicity data in animals reveals relatively high safety margins (42), with oral LD50 values exceeding 5 g/kg body weight in mice (no deaths at maximum tested dose) and intraperitoneal LD50 of 11.46 g/kg. Advanced formulation LD50 studies classify certain preparations as "slightly toxic" at higher concentrations (43).

Acute toxicity studies show no deaths or clinical signs at 500 mg/kg in rats (44), with symptoms at toxic doses including salivation, lethargy, and corneal reflex abnormalities. Histological changes reveal early-stage kidney and liver abnormalities at high doses, indicating dose and structure-dependent organ toxicity (45).

Chronic toxicity studies demonstrate relative safety with appropriate dosing (46), showing no adverse effects at 500 mg/kg daily for 21 days and no reproductive/fertility effects with extracts containing ≥10% andrographolide at 1 g/kg for 86 days. However, purified andrographolide may affect male fertility through decreased sperm count and motility with disruption of spermatogenesis at higher doses (47).

Current Research and Clinical Studies

Research momentum continues accelerating with multiple ongoing clinical trials registered on ClinicalTrials.gov, including long-term follow-up studies evaluating neuroprotective effects in progressive multiple sclerosis patients (48). Emerging therapeutic targets encompass metabolic disorders (type 2 diabetes, hypertriglyceridemia, metabolic syndrome) and neurodegenerative diseases (49).

Novel applications under investigation include COVID-19 treatment (50), with regulatory authorities approving standardized extracts for clinical research. Network pharmacology studies identify potential applications in gastric cancer through 197 targets via HIF-1 and PI3K-Akt signaling pathways (51).

Drug development focuses on structural modifications to improve bioavailability and reduce toxicity, alongside nanotechnology applications including nanocrystals, solid dispersions, and herbosome complexes (52). Bioavailability enhancement strategies show promising results, with cyclodextrin formulations achieving significant improvements in oral absorption (53).

Bioavailability and Pharmacokinetics

Bioavailability challenges significantly impact dosing effectiveness (54), with absolute bioavailability of only 2.67% in humans due to rapid biotransformation, P-glycoprotein-mediated efflux, and poor aqueous solubility. Enhanced formulation strategies including cyclodextrin complexation and surfactant combinations show promise for improving therapeutic outcomes (55).

Pharmacokinetic studies in animal models demonstrate rapid absorption but extensive first-pass metabolism, necessitating innovative delivery systems to achieve therapeutic plasma concentrations (56). Advanced formulation approaches including self-nanoemulsifying drug delivery systems (SNEDDS) have demonstrated 6.3-fold improvements in bioavailability compared to conventional preparations (57).

Quality Control and Analytical Methods

High-Performance Liquid Chromatography (HPLC) serves as the primary analytical method (58), with detection wavelengths at 220nm and 254nm, achieving linear ranges of 100-500 μg/mL with recovery rates of 96.5-99.2%. Validation parameters require specificity confirmation, linearity R² >0.999, precision RSD <2%, accuracy recovery 98-102%, and detection limits of 20-30 ng/mL (59).

International pharmacopeial standards follow hierarchy of stringency: Chinese Pharmacopeia (most stringent) > Hong Kong Standards > European Pharmacopeia > US Pharmacopeia (60). Advanced analytical techniques including LC-MS/MS methods provide enhanced sensitivity and specificity for quality assessment and pharmacokinetic studies (61).

Regulatory Status and FDA Classification

Andrographolide lacks formal pharmaceutical approval in major regulatory jurisdictions, classified instead as a dietary supplement/traditional medicine. The FDA assigns UNII number 410105JHGR without specific safety review as a pharmaceutical agent, while remaining available as botanical products subject to dietary supplement regulations rather than drug approval requirements (62).

International regulatory status varies significantly. Australia's TGA conducted safety reviews due to anaphylactic reactions, while Thailand FDA approved study medication for clinical trials. The compound operates predominantly under dietary supplement frameworks rather than pharmaceutical drug classifications globally.

Dosage Recommendations Based on Clinical Evidence

Recommended adult dosages range from 90-600 mg daily for standardized extracts used up to 12 weeks, typically providing 60-120 mg andrographolide daily (63). Maximum safe doses remain ≤5 mg/kg/day to avoid significant adverse effects, with therapeutic doses commonly standardized to 2-50% andrographolide content.

Pediatric dosing has been studied safely up to 48 mg daily for one month in combination products, though specific pediatric guidelines remain limited for many preparations (64). Clinical studies establish maximum studied safe doses at appropriate therapeutic ranges based on extensive preclinical and clinical research (65).

Conclusion

Andrographolide represents a scientifically validated therapeutic compound with extensive traditional use and modern clinical evidence (66). Its multi-target mechanisms provide therapeutic versatility across inflammatory, infectious, and neoplastic conditions, though bioavailability challenges limit optimal therapeutic translation. The compound demonstrates acceptable safety for short-term use in healthy adults when sourced from reputable manufacturers (67), with injectable derivatives requiring particular caution due to anaphylaxis risks.

Future development depends on addressing bioavailability limitations through innovative formulation strategies while establishing unified global quality standards and expanded clinical research. The growing interest in evidence-based natural health products positions andrographolide as a promising therapeutic agent bridging traditional medicine and modern pharmaceutical science. However, consumers must prioritize quality-controlled products from certified manufacturers and consult healthcare providers for appropriate usage guidance (68), particularly given the complex safety profile and potential drug interactions associated with this potent bioactive compound.

References

1. • Hossain MS, Urbi Z, Sule A, Rahman KM. Andrographolide, a diterpene lactone from Andrographis paniculata and its therapeutic promises in cancer. Chem Biol Interact. 2014;207:68-79. PMID: 24239855. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122281/
2. • PubChem Compound Summary for CID 5318517, Andrographolide. National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/compound/Andrographolide
3. • Lim JC, Chan TK, Ng DS, Sagineedu SR, Stanslas J, Wong WF. Andrographolide and its analogues: versatile bioactive molecules for combating inflammation and cancer. Clin Exp Pharmacol Physiol. 2012;39(3):300-10. https://www.sciencedirect.com/science/article/abs/pii/S0378517324000206
4. • Chao WW, Lin BF. Isolation and identification of bioactive compounds in Andrographis paniculata (Chuanxinlian). Chin Med. 2010;5:17. PMID: 20465823. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876149/
5. • Ye L, Wang H, Duncan SE, Eigel WN, O'Keefe SF. Antioxidant activities of Vine Tea (Ampelopsis grossedentata) extract and its major component dihydromyricetin in soybean oil and cooked ground beef. Food Chem. 2015;172:416-22. https://www.sciencedirect.com/science/article/abs/pii/S0308814614013812
6. • Hossain MS, Urbi Z, Sule A, Rahman KM. Andrographolide, a diterpene lactone from Andrographis paniculata and its therapeutic promises in cancer. Chem Biol Interact. 2014;207:68-79.
7. • Zhang QW, Lin LG, Ye WC. Techniques for extraction and isolation of natural products: a comprehensive review. Chin Med. 2018;13:20. PMID: 29692864. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408759/
8. • Mishra SK, Sangwan NS, Sangwan RS. Andrographis paniculata (Kalmegh): a review. Pharmacogn Rev. 2007;1(2):283-298. https://pmc.ncbi.nlm.nih.gov/articles/PMC4032030/
9. • Hossain MS, Urbi Z, Sule A, Rahman KM. Andrographis paniculata (Burm. f.) Wall. ex Nees: A Review of Ethnobotany, Phytochemistry, and Pharmacology. ScientificWorldJournal. 2014;2014:274905. PMID: 25110721.
10. • Sharma A, Shanker C, Tyagi LK, Singh M, Rao CV. Herbal Medicine for Market Potential in India: An Overview. Acad J Plant Sci. 2008;1(2):26-36.
11. • Kumar S, Singh A, Kumar B, Singh B, Bahadur L, Lal M. Simultaneous quantification of andrographolide and related compounds in Andrographis paniculata extracts and biological evaluation of their anti-inflammatory activity. J Chromatogr Sci. 2023;61(6):514-525. https://academic.oup.com/chromsci/article/61/6/514/7028671
12. • Misra P, Pal NL, Guru PY, et al. Harmonizing international quality standards for Andrographis paniculata: A comparative analysis of content determination methods across pharmacopeias. J Ethnopharmacol. 2024;318:117003. https://www.sciencedirect.com/science/article/abs/pii/S0731708523006933
13. • Li W, Xu X, Zhang H, et al. Purification of andrographolide, a bioactive compound for relieving COVID-19 symptoms, from Andrographis paniculata: Extraction and separation using preparative pulse-injection and adsorption–desorption chromatography. Sep Purif Technol. 2025;354:128250. https://www.sciencedirect.com/science/article/abs/pii/S1383586625025250
14. • Jin Y, Chen C, Guo L, et al. On-line coupling of dynamic microwave-assisted extraction with high-performance liquid chromatography for determination of andrographolide and dehydroandrographolide in Andrographis paniculata Nees. Anal Chim Acta. 2007;580(1):100-5. PMID: 17156791. https://pubmed.ncbi.nlm.nih.gov/17156791/
15. • Kumar S, Singh A, Kumar B, Singh B, Bahadur L, Lal M. Quantitative Determination of Andrographolide and Related Compounds in Andrographis paniculata Extracts and Biological Evaluation of Their Anti-Inflammatory Activity. Molecules. 2020;25(5):1097. PMID: 32121455. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963907/
16. • Pholphana N, Rangkadilok N, Thongnest S, Ruchirawat S, Ruchirawat M, Satayavivad J. Rapid extraction of andrographolide from Andrographis paniculata Nees by three phase partitioning and determination of its antioxidant activity. Biomed Chromatogr. 2016;30(3):428-35. https://www.sciencedirect.com/science/article/abs/pii/S1878818115001188
17. • Wang Y, Zhang Y, Zhu Z, et al. Completing the Biosynthesis of the Clinically Important Diterpenoid Andrographolide in Andrographis Paniculata. Angew Chem Int Ed Engl. 2025;64(2):e202425303. https://onlinelibrary.wiley.com/doi/10.1002/anie.202425303
18. • Wang Y, Zhang Y, Zhu Z, et al. Completing the Biosynthesis of the Clinically Important Diterpenoid Andrographolide in Andrographis Paniculata. Angew Chem. 2025;137(2):e202425303. https://onlinelibrary.wiley.com/doi/10.1002/ange.202425303
19. • Mishra K, Dash AP, Swain BK, Dey N. Anti-malarial activities of Andrographis paniculata and Hedyotis corymbosa extracts and their combination with curcumin. Malar J. 2009;8:26. https://www.sciencedirect.com/science/article/abs/pii/S0031942210002165
20. • Vetvicka V, Vetvickova J. Biological properties of andrographolide, an active ingredient of Andrographis Paniculata: a narrative review. Ann Transl Med. 2021;9(15):1186. PMID: 34430524. https://atm.amegroups.org/article/view/75097/html
21. • Ibrahim MY, Hashim NM, Mariod AA, et al. α-Mangostin from Garcinia mangostana Linn: An updated review of its pharmacological properties. Arab J Chem. 2016;9(3):317-329.
22. • Yang T, Shi HX, Wang ZT, Wang CH. The wide spectrum anti-inflammatory activity of andrographolide in comparison to NSAIDs: A promising therapeutic compound against the cytokine storm. Heliyon. 2024;10(14):e33752. PMID: 39050454. https://pmc.ncbi.nlm.nih.gov/articles/PMC11253928/
23. • Islam MT, Ali ES, Uddin SJ, et al. Comparative pharmacokinetics and safety evaluation of high dosage regimens of Andrographis paniculata aqueous extract after single and multiple oral administration in healthy participants. Front Pharmacol. 2023;14:1230401. PMID: 37521334. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1230401/full
24. • Kapil A, Koul IB, Banerjee SK, Gupta BD. Antihepatotoxic effects of major diterpenoid constituents of Andrographis paniculata. Biochem Pharmacol. 1993;46(1):182-5. PMID: 2228075. https://pubmed.ncbi.nlm.nih.gov/2228075/
25. • Mishra K, Dash AP, Swain BK, Dey N. Andrographolide: A Novel Antimalarial Diterpene Lactone Compound from Andrographis paniculata and Its Interaction with Curcumin and Artesunate. J Trop Med. 2011;2011:579518. PMID: 21765855. https://pmc.ncbi.nlm.nih.gov/articles/PMC3134201/
26. • Hossain MS, Urbi Z, Sule A, Rahman KM. Is there a future for andrographolide to be an anti-inflammatory drug? Deciphering its major mechanisms of action. Biochem Pharmacol. 2014;90(4):645-53. https://www.sciencedirect.com/science/article/abs/pii/S0006295217301880
27. • Islam MT, Ali ES, Uddin SJ, et al. Andrographolide and its derivatives: Current achievements and future perspectives. Eur J Med Chem. 2021;221:113546. https://www.sciencedirect.com/science/article/abs/pii/S0223523421005596
28. • Jiang CG, Li JB, Liu FR, et al. Antiviral Activities of Andrographolide and Its Derivatives: Mechanism of Action and Delivery System. Pharmaceutics. 2021;13(11):1868. PMID: 34834289. https://pmc.ncbi.nlm.nih.gov/articles/PMC8619093/
29. • Burgos RA, Seguel K, Perez M, et al. Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial. BMC Neurol. 2020;20(1):173. PMID: 32381015. https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-020-01745-w
30. • Burgos RA, Seguel K, Perez M, et al. Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial. BMC Neurol. 2020;20(1):173. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203851/
31. • Yang T, Shi HX, Wang ZT, Wang CH. Andrographolide, a natural anti-inflammatory agent: An Update. Front Pharmacol. 2022;13:920435. PMID: 36237504. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.920435/full
32. • Yang T, Shi HX, Wang ZT, Wang CH. Andrographolide, a natural anti-inflammatory agent: An Update. Front Pharmacol. 2022;13:920435. https://pmc.ncbi.nlm.nih.gov/articles/PMC9551308/
33. • Deng C, Zhang B, Zhang S, et al. Exploring the mechanism of andrographolide in the treatment of gastric cancer through network pharmacology and molecular docking. Sci Rep. 2022;12(1):14879. PMID: 36050342. https://www.nature.com/articles/s41598-022-18319-0
34. • Yang T, Shi HX, Wang ZT, Wang CH. Andrographolide, a natural anti-inflammatory agent: An Update. Front Pharmacol. 2022;13:920435.
35. • Zhang CY, Tan BK. Hypotensive activity of aqueous extract of Andrographis paniculata in rats. Clin Exp Pharmacol Physiol. 1996;23(8):675-8.
36. • Serrano NC, Díaz LA, Casas JP, et al. Adverse Effects of Andrographolide Derivative Medications Compared to the Safe use of Herbal Preparations of Andrographis paniculata: Results of a Systematic Review and Meta-Analysis of Clinical Studies. Front Pharmacol. 2022;13:773282. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.773282/full
37. • Serrano NC, Díaz LA, Casas JP, et al. Adverse Effects of Andrographolide Derivative Medications Compared to the Safe use of Herbal Preparations of Andrographis paniculata: Results of a Systematic Review and Meta-Analysis of Clinical Studies. Front Pharmacol. 2022;13:773282.
38. • Serrano NC, Díaz LA, Casas JP, et al. Adverse Effects of Andrographolide Derivative Medications Compared to the Safe use of Herbal Preparations of Andrographis paniculata: Results of a Systematic Review and Meta-Analysis of Clinical Studies. Front Pharmacol. 2022;13:773282. PMID: 35370806.
39. • Memorial Sloan Kettering Cancer Center. Andrographis. https://www.mskcc.org/cancer-care/integrative-medicine/herbs/andrographis
40. • Serrano NC, Díaz LA, Casas JP, et al. Adverse Effects of Andrographolide Derivative Medications Compared to the Safe use of Herbal Preparations of Andrographis paniculata: Results of a Systematic Review and Meta-Analysis of Clinical Studies. Front Pharmacol. 2022;13:773282.
41. • Zhang CY, Tan BK. Mechanisms of cardiovascular activity of Andrographis paniculata in the anaesthetized rat. J Ethnopharmacol. 1999;56(2):97-101.
42. • Zou Y, Lu Y, Wei D. Acute Toxicity and the Effect of Andrographolide on Porphyromonas gingivalis-Induced Hyperlipidemia in Rats. Evid Based Complement Alternat Med. 2013;2013:940284. PMID: 23861706. https://pmc.ncbi.nlm.nih.gov/articles/PMC3703379/
43. • Kumar RA, Sridevi K, Kumar NV, Nanduri S, Rajagopal S. Anticancer and immunostimulatory compounds from Andrographis paniculata. J Ethnopharmacol. 2004;92(2-3):291-5.
44. • Panossian A, Hovhannisyan A, Mamikonyan G, et al. Pharmacokinetic and oral bioavailability of andrographolide from Andrographis paniculata fixed combination Kan Jang in rats and human. Phytomedicine. 2000;7(4):351-64.
45. • Zhang J, Guo L, Chen Y, et al. Acute and subacute toxicity study of andrographolide bioactive in rodents: Evidence for the medicinal use as an alternative medicine. Comp Clin Pathol. 2012;23(6):1505-1515. https://link.springer.com/article/10.1007/s00580-012-1539-x
46. • Nugroho AE, Andrie M, Warditiani NK, et al. Acute Oral Toxicity Evaluation of Andrographolide Self-Nanoemulsifying Drug Delivery System (SNEDDS) Formulation. Drug Des Devel Ther. 2021;15:2833-2840. PMID: 34349480. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291106/
47. • Nugroho AE, Andrie M, Warditiani NK, et al. Acute Oral Toxicity Evaluation of Andrographolide Self-Nanoemulsifying Drug Delivery System (SNEDDS) Formulation. Drug Des Devel Ther. 2021;15:2833-2840. PMID: 34349480. https://pubmed.ncbi.nlm.nih.gov/34349480/
48. • Burgos RA, Seguel K, Perez M, et al. Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial. BMC Neurol. 2020;20(1):173.
49. • Yang T, Shi HX, Wang ZT, Wang CH. Andrographolide, a natural anti-inflammatory agent: An Update. Front Pharmacol. 2022;13:920435.
50. • Islam MT, Ali ES, Uddin SJ, et al. Comparative pharmacokinetics and safety evaluation of high dosage regimens of Andrographis paniculata aqueous extract after single and multiple oral administration in healthy participants. Front Pharmacol. 2023;14:1230401.
51. • Deng C, Zhang B, Zhang S, et al. Exploring the mechanism of andrographolide in the treatment of gastric cancer through network pharmacology and molecular docking. Sci Rep. 2022;12(1):14879.
52. • Pholphana N, Rangkadilok N, Thongnest S, et al. Rapid extraction of andrographolide from Andrographis paniculata Nees by three phase partitioning and determination of its antioxidant activity. Biomed Chromatogr. 2016;30(3):428-35.
53. • Kumar A, Singh SK, Kant R, et al. Enhancing oral bioavailability of andrographolide using solubilizing agents and bioenhancer: comparative pharmacokinetics of Andrographis paniculata formulations in beagle dogs. Pharm Biol. 2024;62(1):116-125. https://pmc.ncbi.nlm.nih.gov/articles/PMC10868414/
54. • Shi MD, Lin HH, Chiang TA, et al. Bioavailability of andrographolide and protection against carbon tetrachloride-induced oxidative damage in rats. Toxicol Appl Pharmacol. 2014;280(1):1-9.
55. • Kumar A, Singh SK, Kant R, et al. Enhancing oral bioavailability of andrographolide using solubilizing agents and bioenhancer: comparative pharmacokinetics of Andrographis paniculata formulations in beagle dogs. Pharm Biol. 2024;62(1):116-125. https://www.tandfonline.com/doi/full/10.1080/13880209.2024.2311201
56. • Zhao T, Tang H, Xie L, et al. Enhancing oral bioavailability of andrographolide via sodium dodecyl sulfate and D-α-Tocopherol polyethylene glycol 1000 succinate copolymer modified nanocrystals. Eur J Pharm Biopharm. 2019;144:142-150.
57. • Lim JC, Chan TK, Ng DS, et al. Sustained release polymer and surfactant based solid dispersion of andrographolide exhibited improved solubility, dissolution, pharmacokinetics, and pharmacological activity. Int J Pharm. 2024;652:123795.
58. • Kumar S, Singh A, Kumar B, Singh B, Bahadur L, Lal M. Simultaneous quantification of andrographolide and related compounds in Andrographis paniculata extracts and biological evaluation of their anti-inflammatory activity. J Chromatogr Sci. 2023;61(6):514-525.
59. • Misra P, Pal NL, Guru PY, et al. Harmonizing international quality standards for Andrographis paniculata: A comparative analysis of content determination methods across pharmacopeias. J Ethnopharmacol. 2024;318:117003.
60. • Misra P, Pal NL, Guru PY, et al. Harmonizing international quality standards for Andrographis paniculata: A comparative analysis of content determination methods across pharmacopeias. J Ethnopharmacol. 2024;318:117003.
61. • Wang JF, Wei DQ, Lin Y, et al. Determination of andrographolide and dehydroandrographolide in rabbit plasma by on-line solid phase extraction of high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;867(1):13-7. PMID: 18371624. https://pubmed.ncbi.nlm.nih.gov/18371624/
62. • FDA Global Substance Registration System. UNII: 410105JHGR. https://precision.fda.gov/uniisearch/srs/unii/410105jhgr
63. • Islam MT, Ali ES, Uddin SJ, et al. Comparative pharmacokinetics and safety evaluation of high dosage regimens of Andrographis paniculata aqueous extract after single and multiple oral administration in healthy participants. Front Pharmacol. 2023;14:1230401.
64. • Islam MT, Ali ES, Uddin SJ, et al. Comparative pharmacokinetics and safety evaluation of high dosage regimens of Andrographis paniculata aqueous extract after single and multiple oral administration in healthy participants. Front Pharmacol. 2023;14:1230401.
65. • Yang T, Shi HX, Wang ZT, Wang CH. Andrographolide, a natural anti-inflammatory agent: An Update. Front Pharmacol. 2022;13:920435.
66. • Serrano NC, Díaz LA, Casas JP, et al. Adverse Effects of Andrographolide Derivative Medications Compared to the Safe use of Herbal Preparations of Andrographis paniculata: Results of a Systematic Review and Meta-Analysis of Clinical Studies. Front Pharmacol. 2022;13:773282.
67. • Serrano NC, Díaz LA, Casas JP, et al. Adverse Effects of Andrographolide Derivative Medications Compared to the Safe use of Herbal Preparations of Andrographis paniculata: Results of a Systematic Review and Meta-Analysis of Clinical Studies. Front Pharmacol. 2022;13:773282.
68. • Yang T, Shi HX, Wang ZT, Wang CH. Andrographolide, a natural anti-inflammatory agent: An Update. Front Pharmacol. 2022;13:920435.